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A deficiency in the activity of the iduronate-2-sulphatase (IDS) gene leads to lysosomal accumulation of heparan and dermatan sulphate fragments, their excretion in urine, and to phenotypic expression of MPS II (Hunter syndrome).' The incidence of the disease has been established to be between 7 5 and 14 8 per million male live births.2 Clinically, the patients may present a wide spectrum of phenotypes. In severely affected patients the lysosomal accumulatic-l of glycosaminoglycans causes progressive damage to the brain, liver, and other organs and severe motor retardation, and leads to death before adulthood. Patients with mild forms survive with little or no mental retardation but frequently suffer bone malformations.
Owing to the X linked recessive inheritance,34 females of MPS II families are at risk of being carriers of the disorder. So Although the enzyme activity in the serum of MPS carriers is about 50% or less compared with the average IDS activity in the serum of healthy persons, there is a broad overlap in the range of specific activities. A cutoff limit of 0 5 for A and of 1-5 for the ratio F + /F -was fixed for the sulphate accumulation test. Only one (family 3, I 1) of the 16 obligate carriers investigated by this method gave an ambiguous result.
Thirty-six females, including the 18 obligate carriers, were investigated by DNA based analysis. Of the 18 potential carriers, 11 were proven to be heterozygous for the MPS II gene and in five women the heterozygous state could be excluded. In two cases RFLP analysis was not informative. These results agree well with those of the biochemical carrier detection tests. As a result of these investigations DNA based prenatal diagnosis could be offered to 27 women (14 of them with the intragenic StuI/ pc2S15 RFLP) (table 2).
We found structural aberrations in only two of the 16 The molecular characterisation of a specific mutation in a patient would allow direct segregation analysis of this defect in the family. Using Southern blotting for deletion screening we found only one deletion in 13 families. The suggested new HindIII restriction site in patient G-117 is localised in the 9-4kb fragment of the IDS structural gene and should result in two smaller fragments. A 3.5 kb fragment containing exon sequences can be detected by the IDS cDNA. The second expected fragment of 5-9 kb contains only intron sequences and was therefore not detectable by the cDNA probe used. The aberrant fragment can be detected in the Southern blot of the patient's mother as well, so it can be used as a direct intragenic segregation marker for MPS II in this family.
In most cases the molecular defect cannot be detected by Southern blotting. The method generally followed for DNA based diagnosis in such families is gene tracking using intragenic and intergenic RFLPs closely linked to the mutation site. The reliability of this indirect genotype analysis is dependent on the crossover rate between the mutation and RFLP sites.
Using the intragenic marker StuI/pc2S15 the error rate caused by recombination should be less than 1%. Recombination fractions between the IDS locus and flanking loci were determined by multipoint analysis.49 No recombination was observed between the IDS locus and the flanking loci DXS296 or DXS466.
The results of the DNA based diagnosis in MPS II families show good agreement with the results of the biochemical diagnosis. About 90% of females are informative for one or more RFLPs and 50%, of them are informative for the intragenic RFLP and another 10% for the closely linked intergenic TaqI/VK21A or TaqI/II-10 RFLPs or both.
At present, the use of the intragenic IDS cDNA probes and flanking probes available so far allows carrier detection in MPS II families 
